| Dr Christopher Mark Reilly, MD | |
|
750 E 34th St, Hibbing, MN 55746-2341 | |
| (218) 262-4881 | |
| (218) 362-6699 |
| Full Name | Dr Christopher Mark Reilly |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 16 Years |
| Location | 750 E 34th St, Hibbing, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659600435 | NPI | - | NPPES |
| 57879 | Other | MN | MN STATE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grand Itasca Clinic And Hospital | Grand rapids, MN | Hospital |
| University Medical Center-mesabi/ Mesaba Clinics | Hibbing, MN | Hospital |
| Community Memorial Hospital | Cloquet, MN | Hospital |
| St Lukes Hospital | Duluth, MN | Hospital |
| Essentia Health Duluth | Duluth, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiologists Associated In Duluth Ltd | 4284547209 | 42 |
| St Lukes Hospital Of Duluth | 7113834839 | 352 |
News Archive
Slow-healing or non-healing bone fractures in otherwise healthy people may be caused by gene variants that are common in the population, according to Penn State College of Medicine researchers.
A new study in the July issue of Health Affairs finds significant regional differences in program spending. Researchers suggest understanding these differences could lead to improved quality and efficiency of care.
A new strategy may help halt the progression of kidney disease in patients with diabetes.
Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.
Since the early development of monoclonal antibodies (mAbs), almost forty years ago, twenty-four therapeutic mAbs have been approved, four of them targeting digestive system cancers. Due to this success (two blockbusters reaching sales of over $1 billion), many industrials position themselves on this very attractive sector.
› Verified 9 days ago
| Entity Name | Radiologists Associated In Duluth Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598722688 PECOS PAC ID: 4284547209 Enrollment ID: O20031106000469 |
News Archive
Slow-healing or non-healing bone fractures in otherwise healthy people may be caused by gene variants that are common in the population, according to Penn State College of Medicine researchers.
A new study in the July issue of Health Affairs finds significant regional differences in program spending. Researchers suggest understanding these differences could lead to improved quality and efficiency of care.
A new strategy may help halt the progression of kidney disease in patients with diabetes.
Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.
Since the early development of monoclonal antibodies (mAbs), almost forty years ago, twenty-four therapeutic mAbs have been approved, four of them targeting digestive system cancers. Due to this success (two blockbusters reaching sales of over $1 billion), many industrials position themselves on this very attractive sector.
› Verified 9 days ago
| Entity Name | St Lukes Hospital Of Duluth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902845068 PECOS PAC ID: 7113834839 Enrollment ID: O20031120000212 |
News Archive
Slow-healing or non-healing bone fractures in otherwise healthy people may be caused by gene variants that are common in the population, according to Penn State College of Medicine researchers.
A new study in the July issue of Health Affairs finds significant regional differences in program spending. Researchers suggest understanding these differences could lead to improved quality and efficiency of care.
A new strategy may help halt the progression of kidney disease in patients with diabetes.
Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.
Since the early development of monoclonal antibodies (mAbs), almost forty years ago, twenty-four therapeutic mAbs have been approved, four of them targeting digestive system cancers. Due to this success (two blockbusters reaching sales of over $1 billion), many industrials position themselves on this very attractive sector.
› Verified 9 days ago
| Entity Name | Community Memorial Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003869082 PECOS PAC ID: 0042129991 Enrollment ID: O20040202001203 |
News Archive
Slow-healing or non-healing bone fractures in otherwise healthy people may be caused by gene variants that are common in the population, according to Penn State College of Medicine researchers.
A new study in the July issue of Health Affairs finds significant regional differences in program spending. Researchers suggest understanding these differences could lead to improved quality and efficiency of care.
A new strategy may help halt the progression of kidney disease in patients with diabetes.
Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.
Since the early development of monoclonal antibodies (mAbs), almost forty years ago, twenty-four therapeutic mAbs have been approved, four of them targeting digestive system cancers. Due to this success (two blockbusters reaching sales of over $1 billion), many industrials position themselves on this very attractive sector.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Mark Reilly, MD 23 W Central Entrance # 160, Duluth, MN 55811-3433 Ph: (218) 722-3700 | Dr Christopher Mark Reilly, MD 750 E 34th St, Hibbing, MN 55746-2341 Ph: (218) 262-4881 |
News Archive
Slow-healing or non-healing bone fractures in otherwise healthy people may be caused by gene variants that are common in the population, according to Penn State College of Medicine researchers.
A new study in the July issue of Health Affairs finds significant regional differences in program spending. Researchers suggest understanding these differences could lead to improved quality and efficiency of care.
A new strategy may help halt the progression of kidney disease in patients with diabetes.
Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.
Since the early development of monoclonal antibodies (mAbs), almost forty years ago, twenty-four therapeutic mAbs have been approved, four of them targeting digestive system cancers. Due to this success (two blockbusters reaching sales of over $1 billion), many industrials position themselves on this very attractive sector.
› Verified 9 days ago
Frank J Suslavich, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 750 E 34th St, Hibbing, MN 55746 Phone: 218-262-4881 Fax: 218-362-6699 | |
Michael T Semotuk, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 750 E 34th St, Hibbing, MN 55746 Phone: 218-262-4881 Fax: 218-362-6699 | |
Dr. Daniel Scott Vechell, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1200 E 25th St, Hibbing, MN 55746 Phone: 218-312-3005 Fax: 218-312-3003 | |
Dr. Gerald Thomas Mccullough, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 750 E 34th St, Hibbing, MN 55746 Phone: 218-262-4881 Fax: 218-362-6699 | |
Anne T Goldschmidt, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 750 E 34th St, Hibbing, MN 55746 Phone: 218-262-4881 Fax: 218-362-6699 | |
William Schwartau, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 750 E 34th St, Hibbing, MN 55746 Phone: 218-362-6683 Fax: 218-362-6684 |